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Abstract
Objectives To evaluate the impact of preoperative sepsis on risk of
postoperative arterial and venous thromboses.
Design Prospective cohort study using the National Surgical Quality
Improvement Program database of the American College of Surgeons
(ACS-NSQIP).
Setting Inpatient and outpatient procedures in 374 hospitals of all types
across the United States, 2005-12.
Participants 2 305 380 adults who underwent surgical procedures.
Main outcome measures Arterial thrombosis (myocardial infarction or
stroke) and venous thrombosis (deep venous thrombosis or pulmonary
embolism) in the 30 days after surgery.
Results Among all surgical procedures, patients with preoperative
systemic inflammatory response syndrome or any sepsis had three times
the odds of having an arterial or venous postoperative thrombosis (odds
ratio 3.1, 95% confidence interval 3.0 to 3.1). The adjusted odds ratios
were 2.7 (2.5 to 2.8) for arterial thrombosis and 3.3 (3.2 to 3.4) for venous
thrombosis. The adjusted odds ratios for thrombosis were 2.5 (2.4 to
2.6) in patients with systemic inflammatory response syndrome, 3.3 (3.1
to 3.4) in patients with sepsis, and 5.7 (5.4 to 6.1) in patients with severe
sepsis, compared with patients without any systemic inflammation. In
patients with preoperative sepsis, both emergency and elective surgical
procedures had a twofold increased odds of thrombosis.
Conclusions Preoperative sepsis represents an important independent
risk factor for both arterial and venous thromboses. The risk of thrombosis
increases with the severity of the inflammatory response and is higher
in both emergent and elective surgical procedures. Suspicion of
thrombosis should be higher in patients with sepsis who undergo surgery.
Introduction
Arterial and venous thromboses are common serious
postoperative complications. More than 4% of surgical
procedures are followed by an arterial thrombosis1 and at least
another 4% by venous thrombosis.2 3 Several risk factors have
been identified, such as existing coronary atherosclerosis for
the former and older age, male sex, previous venous
thromboembolism, and malignancy for the latter. There are,
however, few data on the risk of postoperative thrombosis
associated with infection.
Systemic infections with their consequent inflammation and
hypercoagulable state might affect risk of postoperative
thrombosis. Indeed, a persistent proinflammatory response has
long been recognised as a major determinant of myocardial
infarction and stroke as well as deep vein thrombosis and
pulmonary embolism.4 5 Similarly, infection can activate a
hypercoagulable state, inducing platelet activation, production
of tissue factor, and increased fibrin turnover, which can all lead
to thrombotic complications.6-10 Finally, indirect factors such as
hypoxaemia and hypotension can also represent triggers for
arterial thrombosis.
Better evaluation of the impact of infection and its severity in
postoperative thrombotic complication could help in the
prevention of thrombotic events among surgical patients. To
determine whether an association exists between preoperative
sepsis and the risk of arterial and venous thromboses in the
postoperative period, we compared the risk of arterial and
venous thromboses in patients with and without preoperative
sepsis in a large multicentre surgical cohort.
Methods
Setting
We used data from the American College of Surgeons National
Surgical Quality Improvement Program (ACS-NSQIP).11 The
ACS-NSQIP is a validated prospective cohort study of a random
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sample of inpatients and outpatients undergoing non-trauma
major surgery in up to 374 academic and community hospital
across the United States. Trained abstractors use strict standard
definitions to collect data at an institutional level, with regular
audit to ensure reliability and quality. Data collected include
preoperative risk factors, procedures performed by Current
Procedural Terminology (CPT) code, and postoperative
complications occurring within 30 days of the index operation.
Our study followed strengthening of reporting observational
studies in epidemiology (STROBE) guidelines.12
Study population
We evaluated all adult patients aged ≥18 who underwent
non-trauma major surgery from 1 July 2005 to 31 December
2012. A surgical procedure was considered as major for all
procedures carried out under general, spinal, or epidural
anaesthesia, as well as the following procedures regardless of
the type of anaesthesia: carotid endarterectomy, inguinal hernia
repair, parathyroidectomy, thyroidectomy, breast lumpectomy,
endovascular abdominal aortic aneurysm repair. Patients were
not eligible if they had had a previous operative procedure in
the past 30 days. We abstracted the following elements from
the database for analysis: age, sex, race, bodymass index (BMI),
smoking status, treated arterial hypertension, diagnosis of
diabetes, severe renal failure, disseminated cancer, bleeding
disorder, surgical subspecialty, emergency versus
non-emergency surgical procedure, and local versus general
anaesthesia. An emergency procedure is performed within a
short interval of time between diagnosis or the onset of related
preoperative symptoms. Because non-emergency surgical
procedures can include semi-urgent cases, we also used the
elective and non-elective criteria available only in the 2011-2012
datasets. Patients undergoing elective procedures are brought
to the hospital or facility for a scheduled surgery from their
home or normal living situation on the day that the procedure
is performed.
Exposure
Trained abstractors at each site identified and categorised
patients with a systemic inflammatory response during the 48
hours before the surgical procedure according to systemic
inflammatory response syndrome (SIRS), sepsis, or severe
sepsis/septic shock.13 The systemic inflammatory response
syndrome was defined by the presence of two or more of
temperature >38°C or <36°C; heart rate >90 beats/minute;
respiratory rate >20 breaths/minute or a PaCO2 <32 mm Hg
(<4.3 kPa); white blood cell count >12 000 cell/mm3, <4000
cells/mm3, or >10% immature band forms; or anion gap acidosis
(>12 mEq/L). Sepsis was defined as systemic inflammatory
response syndrome plus one of a positive result on blood culture,
clinical documentation of purulence, or positive result on culture
from any site thought to be causative. Severe sepsis/septic shock
was defined as the presence of sepsis associated with an organ
and/or circulatory dysfunction (such as oliguria, acute alteration
in mental status, acute respiratory distress/hypotension,
requirement for inotropic or vasopressor agents).
By definition, systemic inflammatory response syndrome does
not include inflammatory processes in which a bacterial infection
is already proved. Therefore, it includes other inflammation
processes, such as latent bacterial infection, viral infection (for
example, sore throat, bronchitis, flu), or an inflammatory
response without infection.
Study outcome
Our primary outcomes were any arterial or venous thrombosis
that occurred intraoperatively or within 30 days after a surgical
procedure, including acute myocardial infarction or stroke for
arterial thrombosis and deep venous thrombosis or pulmonary
embolism for venous thrombosis. Trained abstractors at each
site determined acute myocardial infarction according to the
following definition: ST elevation >1 mm in two or more
contiguous leads on the electrocardiogram, new left bundle
branch, new Q wave in two of more contiguous leads, new
increase in troponin concentrations to over three times the upper
concentration of the reference range in the setting of suspected
myocardial ischaemia, or myocardial infarction diagnosed by
a physician. A stroke was an embolic, thrombotic, or
haemorrhagic vascular event or stroke with motor, sensory, or
cognitive dysfunction (such as hemiplegia, hemiparesis, aphasia,
sensory deficit, impaired memory) that persisted for 24 or more
hours. A deep venous thrombosis was defined as a new blood
clot or thrombus within the venous system confirmed by duplex
ultrasongraphy, venography, or computed tomography, and the
patient must have been treated with anticoagulation and/or
placement of vena cava filter or clipping of the vena cava. A
pulmonary embolism was defined by the presence of a blood
clot in a pulmonary artery with subsequent obstruction of blood
supply to the lung parenchyma or if the patient had a
ventilation-perfusion scan interpreted as high probability of
pulmonary embolism or a positive result on spiral computed
tomography, transoesophageal echocardiography, pulmonary
arteriography, or computed tomography angiography. Secondary
outcomes were the acute myocardial infarction, stroke, deep
venous thrombosis and pulmonary embolism separately, as well
as overall 30 day postoperative mortality.
Statistical analysis
Proportions for baseline characteristics were calculated for
patients without any systemic inflammatory response, patients
with any systemic inflammatory response or sepsis, patients
with systemic inflammatory response syndrome, patients with
sepsis, and patients with severe sepsis/septic shock within 48
hours before the surgical procedure. For the four groups with a
preoperative systemic inflammatory response, we calculated
crude and adjusted odds ratios for the outcomes. To obtain the
adjusted odds ratios with 95% confidence intervals, we adjusted
multivariable logistic regression for age, sex, diabetes mellitus,
smoking status, treated arterial hypertension, renal failure,
cancer, bleeding disorder or anticoagulation, general anaesthesia,
and surgical subspecialty. Missing data were extremely rare
(four covariates had missing data for one or more case(s), with
a maximum of 0.02%), but if present they were coded as dummy
variables in the analysis. When no information on exposure
(preoperative sepsis) was available, the case was excluded from
the analysis. Because missing data for exposure are missing at
random (that is, without relation to the presence or absence of
the exposure), validity of the results is preserved.14
No outcome data weremissing.We performed stratified analyses
separately for the outcomes of arterial and venous thromboses
and adjusted for the same variables as in the multivariable
logistic regression. Stratified results are presented as forest plots.
For each stratified analysis, we tested the P value for equal odds
ratios across subgroups by the P value for an interaction term
between sepsis and thrombosis in the model. Regression logistic
model showed an interaction between subgroup and the adjusted
variables so that the stratified model and interaction model were
equivalent. All P values are two tailed, and confidence intervals
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were calculated at the 95% level. All statistical analyses were
performed with SAS version 9.3 (SAS Institute, Cary, NC).
Results
In total, 2 320 920 surgical cases were identified in the
ACS-NSQIP cohort during the study period (fig 1).⇓ Of these,
3268 (0.1%) were excluded because patients were aged under
18 at time of the surgical procedure. We further excluded 12
272 (0.5%) cases without available information on the existence
of preoperative sepsis. Our final cohort for the analyses
comprised 2 305 380 surgical cases. Preoperative sepsis of any
grade was present in 167 986 patients (7.3%): 103 479 (4.5%)
had systemic inflammatory response syndrome, 48 735 (2.1%)
had sepsis, and 15 772 (0.7%) had severe sepsis/septic shock.
The prevalence of preoperative sepsis was similar across the
categories of age, race, and sex (table 1).⇓ Preoperative sepsis
was more common in patients with diabetes, renal failure,
bleeding disorders; smokers; and patients having general
surgery. Non-emergency procedures were less common in
patients with sepsis.
Risk of postoperative arterial and venous
thromboses associated with systemic
inflammatory response
The presence of preoperative sepsis increased the overall risk
of postoperative arterial and venous thromboses by three times
(odds ratio 3.1, 95% confidence interval 3.0 to 3.1) (table 2).⇓
When we stratified the risk of thrombosis by severity of sepsis,
the risk increased with severity: the adjusted odds ratio was 2.5
(95% confidence interval 2.4 to 2.6) in patients with systemic
inflammatory response syndrome, 3.3 (3.1 to 3.4) in patients
with sepsis, and 5.7 (5.4 to 6.1) in patients with severe sepsis.
Risk of arterial thrombosis
The odds ratio for arterial thrombosis in patients with any
preoperative sepsis was 2.7 (95% confidence interval 2.5 to 2.8)
compared with patients without sepsis (table 2).⇓ The adjusted
odds ratios ranged from 2.2 to 5.0 according to the severity of
the preoperative sepsis. Although the postoperative risk was
similar for both myocardial and stroke (odds ratio 2.7 v 2.6,
respectively), the risk of having a stroke was about two thirds
higher than risk of myocardial infarction in patients with
preoperative severe sepsis, with odds ratios of 6.1 (5.3 to 6.9)
and 4.1 (3.7 to 4.6), respectively.
Subgroup analysis for arterial thrombosis
While none of the baseline characteristics changed the overall
association between preoperative sepsis and the risk of
postoperative arterial thrombosis, the effect of sepsis seemed
to be lower with increasing age (odds ratio 4.5 in patients aged
≤40 v 2.0 in patients >80) (fig 2).⇓ Also, men had a lower risk
of arterial thrombosis than women (odds ratio 2.4 v 3.0,
interaction P<0.001). Similarly, patients with diabetes had a
lower risk of arterial thrombosis than those without diabetes.
Patients with disseminated cancer and preoperative sepsis had
a lower risk of postoperative arterial thrombosis than patients
without cancer (odds ratio 1.9 v 2.7, P=0.004). Finally, patients
undergoing cardiac surgery had a lower risk of arterial
thrombosis compared with other subspecialties.
We found no effect modification for BMI, smoking status, or
type of anaesthesia (general v local). Emergency,
non-emergency, elective, and non-elective procedure categories
also all had a similar odds ratio between 1.9 and 2.0, without
significant effect modification (P>0.10).
Among patients without diabetes, the proportion of arterial
thrombosis increased from 0.40% in those without preoperative
sepsis to 1.34% in those with preoperative sepsis (odds ratio
3.4). Among patients with diabetes, the proportion increased
from 1.07% to 2.49%, respectively (odds ratio 2.4). Among
patients without cancer, the proportion of arterial thrombosis
increased from 0.49% in those without preoperative sepsis to
1.56% in those with preoperative sepsis (odds ratio 3.2). Among
patients with cancer, the proportion increased from 0.87 to
1.83%, respectively (odds ratio 2.1).
Risk of venous thrombosis
When we evaluated the risk of postoperative venous thrombosis
specifically, the overall risk was higher than for arterial
thrombosis, with an odds ratio of 3.3 (95% confidence interval
3.2 to 3.4) in case of preoperative sepsis (table 2).⇓ This risk
ranged from 2.6 to 6.1 according to severity. The risk of
postoperative deep venous thrombosis was about two thirds
higher than the risk of pulmonary embolism when a sepsis was
present before the surgical procedure (odds ratio 3.7 v 2.4,
respectively). This difference of risk increased with severity of
sepsis, with almost a 2.5 times higher risk of deep venous
thrombosis than pulmonary embolism in patients with severe
sepsis.
Subgroup analysis for venous thrombosis
The risk of postoperative venous thrombosis associated with
sepsis was not affected by most baseline characteristics (fig 3).⇓
The risk was constant across and within all subgroups, except
for patients with a disseminated cancer or a bleeding disorder
and patients from a cardiac subspecialty (P<0.001 for
interaction). The risk of venous thrombosis was also
independently increased in both emergency and non-emergency
procedures, but with a significant higher risk for non-emergency
procedures (odds ratio 3.3 v 2.1, P<0.001). Conversely, for
elective procedures in patients with preoperative sepsis there
was a twofold increased odds for postoperative venous
thrombosis (odds ratio 2.0, 95% confidence interval 1.8 to 2.1)
in the 2011-12 year dataset (n=986 034). The odds ratio was
significantly higher for patients undergoing non-elective
procedures (3.3, 2.8 to 3.9).
Among patients without cancer, the proportion of venous
thrombosis increased from 0.74% in those without preoperative
sepsis to 2.66% in those with preoperative sepsis (odds ratio
3.7). Among patients with cancer, the proportion increased from
2.77% to 4.82%, respectively (odds ratio 1.8). The proportion
of venous thrombosis was therefore higher in patients with
cancer (4.82% v 2.66%), but the association between sepsis and
venous thrombosis was less strong (odds ratio 3.7 v 1.8). Among
patients with non-emergency procedure, the proportion of
venous thrombosis increased from 0.74% in those without
preoperative sepsis to 2.73% in those with preoperative sepsis
(odds ratio 3.8). In comparison, among patients with emergent
procedure, the proportion increased from 1.26% to 2.73%,
respectively (odds ratio 2.2).
Secondary analyses
Compared with patients who did not fulfil any of the criteria
for preoperative sepsis, those with preoperative sepsis had a
higher risk of 30 day postoperative mortality (adjusted odds
ratio 9.2, 95% confidence interval 9.0 to 9.5). The odds ratios
ranged from 5.9 (5.7 to 6.1) for patients with systemic
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inflammatory response syndrome to 7.6 (7.3 to 7.9) for patients
with sepsis and up to 42.3 (40.6 to 44.0) for patients with severe
sepsis.
Discussion
In this large observational cohort of 2.3 million surgical
procedures performed across the US from 2005 to 2012,
preoperative sepsis was an important independent risk factor
for both arterial and venous thromboses, with about three times
the risk of each of these complications compared with patients
without evidence of preoperative sepsis. Risk was increased
more than twofold among those with a systemic inflammation
response without proved infection and became higher as the
severity of sepsis increased. This increased risk of postoperative
thrombosis was present in patients undergoing elective as well
as emergency operations and persisted in analyses stratified by
age, sex, smoking status, blood pressure, and diabetes. Increased
risks for postoperative arterial and venous thromboses were
associated with preoperative infection or inflammation among
patients with and without cancer and were present in all surgical
specialties evaluated.
Our results make clinical sense, as we could expect a potential
increased risk of thrombosis in patients with sepsis. To our
knowledge, however, previous research has not determined the
burden of arterial or venous thrombosis in the context of sepsis,
particularly in surgical patients. Studies have focused on
critically ill patients and most were limited in size.15 We
quantified the risk for both arterial and venous thromboses and
evaluated the contribution from the degree of clinical systemic
inflammation.
Although it might at first seem surprising that the risk of venous
thrombosis is lower in subgroups of patients with cancer and
in cardiac specialties (fig 3),⇓ these results can be explained by
a typically large use of thromboprophylaxis in such patients
because of their underlying risk for thrombosis. Moreover, a
higher relative increase risk among patients without cancer and
those undergoing non-emergency procedures, but with a lower
absolute risk as shown in our results, might also contribute to
these findings.
Infection, inflammation, and arterial
thrombosis
While some early case-control studies suggested a link between
specific infections and an increased risk of myocardial infarction
and stroke, these effects have generally not been observed in
larger prospective cohort studies with better adjustment for
confounding. Furthermore, several randomised trials of antibiotic
treatment failed to show that eradication of infection reduced
arterial event rates.16Abundant evidence from the past 20 years,
however, has shown that individuals with a pro-inflammatory
response are at significantly increased risks for myocardial
infarction and stroke, both on a short and long term basis.17-21
Acute infection induces such a pro-inflammatory response, and,
in our cohort, we found that sepsis was independently associated
with an odds ratio of 2.2 to 5.0 for arterial thrombosis. This is
comparable with the effect magnitude of most important
predictors of perioperative cardiac risk, such as a history of
congestive heart failure, a history of cerebrovascular disease,
and high risk surgery, that have an odds ratio between 1.9 and
2.8.1 22
In contrast with the latter factors, more action could be taken
to reduce cardiovascular risk in patients with sepsis. Strategies
to improve outcomes might include improving cardiovascular
protection in these patients and, whenever possible,
postponement of the surgical procedure as much as possible to
treat the sepsis first. While an urgent surgical procedure might
be the most appropriate treatment for sepsis, in our study many
surgical procedures coded as elective were performed in patients
with sepsis. Randomised trials have shown treatment with statins
can substantially reduce arterial vascular events among
individuals selected for a pro-inflammatory response as detected
by increased concentrations of C reactive protein.23
Infection, inflammation, and venous
thrombosis
Evidence to support the use of thromboprophylaxis in patients
with sepsis relies mainly on data extrapolated from critically ill
patients.24 Patients in intensive care units have an increased risk
of venous thromboembolism.25-27 With a prevalence of sepsis
between 17% and 52% in these populations, the rationale was
that patients with severe sepsis would be at similar or higher
risk. While such recommendation exists for general critically
ill patients with severe sepsis, no specific recommendation exists
specifically for surgical patients with any severity of sepsis.
The American College of Chest Physicians (ACCP)
recommendations for thromboprophylaxis in surgical patients
are based on risk stratification.2The predictionmodels, however,
are not well validated. One of the two recommended prediction
models—the Rogers score—doesn’t include sepsis or a
pro-inflammatory response as predictors.28 Sepsis is part of the
Caprini model but adds little risk.29 30 Based on this model, an
isolated risk factor of sepsis would attribute a low risk of venous
thromboembolism (around 0.7%). This contrasts with the 2.7%
prevalence found in our large cohort study (see table 2⇓). As
only half of critically ill patients with sepsis are known to
receive thromboprophylaxis,31many surgical patients with sepsis
might benefit from thromboprophylaxis as a simple and efficient
way of preventing venous thromboembolism.32 As with arterial
thrombosis, randomised placebo controlled trials have shown
that treatment with statins reduces the risk of deep vein
thrombosis and pulmonary embolism among individuals selected
for a heightened pro-inflammatory response.33
Physiopathological assumptions
Although a causal role is not yet proved, several investigations
support the hypothesis that inflammation contributes to
atherogenesis.5-34 Sepsis could induce a higher risk of arterial
and venous thromboses by several possible mechanisms:
endothelial injury and dysfunction from endotoxin release;
platelet aggregation and a procoagulant state; changes in lipid
metabolism; and smooth muscle proliferation. Recent work also
implicates leucocyte activation, mast cells, and monocytes in
atherogenesis.35 36 Partly on this basis, two multinational trials
are now under way directly testing the inflammatory hypothesis
of atherothrombosis: the National Institutes of Health funded
cardiovascular inflammation reduction trial (CIRT) testing low
dose methotrexate and the industry funded canakinumab
anti-inflammatory thrombosis outcomes study (CANTOS)
evaluating interleukin-1β.37 It seems unlikely that hypotension
and hypoxaemia secondary to sepsis play a major role as these
factors would be less likely to result in venous
thromboembolism. Therefore, other factors that could
concomitantly explain both arterial and venous thromboses are
more likely.
Limitations of study
This study has several limitations. Firstly, we used an
observational cohort that limits our ability to evaluate
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associations. The dataset, however, is large, multi-institutional,
and of high quality. Furthermore, the effect gradient across
levels of sepsis severity provides strong support for our
hypothesis. Secondly, we were unable to use a mixed effect
model to account for hospital clustering, although this would
only slightly increase the confidence interval and not modify
the effect estimates. Thirdly, we had no information about drugs
patients were taking. For example, patients taking statins might
be less likely to have an arterial or venous thrombosis, and
patients taking anticoagulants and antithrombotic treatments
might be less likely to have venous thrombosis. We also did not
have data on genetic determinants of thrombosis such as factor
V Leiden, which is known to increase rates of deep vein
thrombosis and pulmonary embolism. Fourthly, because of
increases in cardiac troponin in some cases of sepsis, we cannot
completely exclude an overdiagnosis of arterial thrombosis in
these patients, although an isolated increase in troponin was not
a sufficient criterion to determine the presence of arterial
thrombosis. Finally, despite the presence of an exhaustive list
of factors collected in this cohort and the careful selection of
the covariates to adjust for, we cannot fully exclude residual
confounding.
Implications
Our results have several clinical implications. Firstly, though
it is obvious to avoid any elective surgical procedure in patients
with sepsis and severe sepsis, it is interesting to see here that
even patients with systemic inflammatory response syndrome
have a significantly increased risk of postoperative thrombosis.
Therefore, elective procedure should be avoided as much as
possible in such patients, and a careful benefit-risk evaluation
of the surgical procedure should include any grade of sepsis as
a risk factor for both arterial and venous thromboses. Secondly,
thromboprophylaxis should be considered in surgical patients
with preoperative sepsis. Although sepsis has been found to be
a risk factor for venous thrombosis in medical patients, our
findings support consideration of thromboprophylaxis in surgical
patients with preoperative sepsis. A trial would be helpful to
definitively address this issue. Finally, cardiovascular protection
should be promoted in patients with preoperative sepsis
according to their other risk factors.
Conclusions
Preoperative sepsis was a major determinant of postoperative
arterial and venous thromboses in almost all surgical settings.
This risk was already clinically important in early stages of
sepsis without a proved infectious agent and increased with the
severity of sepsis. The risk of arterial and venous thromboses
should be recognised in preoperative patients with any grade of
sepsis, and postponement of the surgical procedure should be
considered whenever possible. Also, adequate
thromboprophylaxis and cardiac protection should be considered
in all patients presenting with preoperative sepsis of any severity.
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Tables
Table 1| Characteristics of cohorts of surgical cases (n=2 305 380) according to presence of sepsis before surgery. Figures are numbers
(percentage) unless stated otherwise
Sepsis severity
Any sepsis (n=167
986)
No sepsis (n=2 137
394)
Severe sepsis‡
(n=15 772)Sepsis† (n=48 735)SIRS* (n=103 479)
Age (years):
1149 (7.3)9 411 (19.3)30 498 (29.5)41 058 (24.4)376 393 (17.6)18-39
4623 (29.3)17 262 (35.4)32 185 (31.1)54 070 (32.2)813 859 (38.1)40-59
7438 (47.2)16 536 (33.9)29 519 (28.5)53 493 (31.8)770 646 (36.1)60-79
2562 (16.2)5526 (11.3)11 277 (10.9)19 365 (11.5)176 496 (8.3)≥80
8045 (51.1)25 303 (52.0)50 016 (48.4)83 364 (49.7)899 352 (42.2)Male
Race:
11 045 (70.0)31 757 (65.2)69 229 (66.9)112 031 (66.7)1 517 328 (71.0)White
644 (4.1)3294 (6.8)8150 (7.9)12 088 (7.2)119 617 (5.6)Hispanic
2040 (12.9)7282 (14.9)11 412 (11.0)20 734 (12.3)199 684 (9.3)Black
2043 (13.0)6402 (13.1)14 688 (14.2)23 133 (13.8)300 765 (14.1)Other/unknown
27.9 (23.4-33.9)27.5 (23.5-32.8)27.3 (23.3.-32.2)27.4 (23.4-32.5)28.3 (24.4-33.5)Median (IQR) BMI
Comorbidities:
4 117 (26.1)13 188 (27.1)26 100 (25.2)43 405 (25.8)408 899 (19.1)Current smokers within
1 year
10 096 (64.0)25 035 (51.4)44 037 (42.6)79 168 (47.1)984 295 (46.1)Treated arterial
hypertension
4506 (28.6)12 208 (25.1)16 634 (16.1)33 348 (19.9)313 322 (14.7)Diabetes mellitus
2494 (15.8)3137 (6.4)3582 (3.5)9213 (5.5)31 124 (1.5)Severe renal failure§
754 (4.8)1813 (3.7)3433 (3.3)6000 (3.6%)40 479 (1.9)Disseminated cancer
4 288 (27.2)6 581 (13.5)11 363 (11.0)22 232 (13.2)99 689 (4.7)Bleeding disorder¶
Surgical subspecialty:
13 430 (85.2)39 051 (80.1)83 997 (81.2)136 478 (81.2)1 329 263 (62.2)General
1895 (12.0)6196 (12.7)12 071 (11.7)20 162 (12.0)252 582 (11.8)Thoracic and
cardiovascular
190 (1.2)1655 (3.4)3690 (3.6)5535 (3.2)232 374 (10.9)Orthopaedic
35 (0.2)281 (0.6)1036 (1.0)1352 (0.8)102 475 (4.8)Gynaecology
222 (1.4)1552 (3.2)2685 (2.6)4459 (2.7)220 700 (10.3)Other**
3480 (22.1)20 660 (42.4)45 461 (43.9)69 601 (41.4)1 967 887 (92.1)Non-emergency cases
15 528 (98.5)46 461 (95.3)100 190 (96.8)162 169 (96.5)1 931 770 (90.4)General anaesthesia
SIRS=systemic inflammatory response syndrome; IRQ=interquartile range.
*Defined by presence of two or more of: body temperature >38°C or <36°C; heart rate >90 beats/min; respiratory rate >20 breaths/min or PaCO2 <32 mm Hg;
white blood cells >12<thin>000 cell/mm3, <4000 cells/mm3, or >10% immature (band) forms; anion gap acidosis.
†SIRS plus one of: positive result on blood culture; clinical documentation of purulence or positive culture from any site thought to be causative.
‡Sepsis and documented organ and/or circulatory dysfunction.
§Acute or chronic renal failure requiring treatment with peritoneal dialysis, haemodialysis, haemofiltration, haemodiafiltration, or ultrafiltration within 2 weeks before
surgery.
¶Because of deficiency of blood clotting elements (for example, vitamin K deficiency, haemophilias, thrombocytopenia, chronic
anticoagulation therapy that has not been stopped before surgery).
**Neurosurgery, urological surgery, otolaryngology surgery, plastic surgery, other/unknown.
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Table 2| Crude and adjusted odds ratios (95% confidence interval) for having thrombosis within 30 days after intervention according to
presence of sepsis before surgery
Sepsis severity
Any sepsis (n=167 986) Severe sepsis‡ (n=15 772)Sepsis† (n=48 735)SIRS* (n=103 479)
Composite endpoint for arterial or venous thromboses
1526 (9.7)2220 (4.6)3272 (3.2)7018 (4.2)No (%)
8.5 (8.0 to 9.0)3.8 (3.6 to 4.0)2.6 (2.5 to 2.7)3.5 (3.4 to 3.5)Crude odds ratio
5.7 (5.4 to 6.1)3.3 (3.1 to 3.4)2.5 (2.4 to 2.6)3.1 (3.0 to 3.1)Adjusted odds ratio§
Arterial thrombosis
614 (3.9)771 (1.6)1247 (1.2)2632 (1.6)No (%)
8.1 (7.5 to 8.8)3.2 (3.0 to 3.5)2.4 (2.3 to 2.6)3.2 (3.0 to 3.3)Crude odds ratio
5.0 (4.6 to 5.4)2.6 (2.4 to 2.8)2.2 (2.1 to 2.4)2.7 (2.5 to 2.8)Adjusted odds ratio§
Myocardial infarction
352 (2.2)545 (1.1)746 (0.7)1643 (1.0)No (%)
7.6 (6.8 to 8.5)3.8 (3.5 to 4.1)2.4 (2.2 to 2.6)3.3 (3.1 to 3.5)Crude odds ratio
4.1 (3.7 to 4.6)2.9 (2.6 to 3.1)2.1 (2.0 to 2.3)2.6 (2.5 to 2.8)Adjusted odds ratio§
Stroke
276 (1.8)244 (0.5)536 (0.5)1056 (0.6)No (%)
8.6 (7.6 to 9.7)2.4 (2.1 to 2.8)2.5 (2.3 to 2.7)3.0 (2.8 to 3.3)Crude odds ratio
6.1 (5.3 to 6.9)2.1 (1.9 to 2.4)2.4 (2.2 to 2.6)2.7 (2.5 to 2.9)Adjusted odds ratio§
Venous thrombosis
960 (6.1)1509 (3.1)2121 (2.1)4590 (2.7)No (%)
8.3 (7.7 to 8.8)4.1 (3.9 to 4.3)2.7 (2.6 to 2.8)3.6 (3.5 to 3.7)Crude odds ratio
6.1 (5.7 to 6.5)3.7 (3.5 to 3.9)2.6 (2.5 to 2.7)3.3 (3.2 to 3.4)Adjusted odds ratio§
Pulmonary embolism
174 (1.1)377 (0.8)657 (0.6)1208 (0.7)No (%)
3.8 (3.2 to 4.4)2.6 (2.4 to 2.9)2.1 (2.0 to 2.3)2.4 (2.2 to 2.6)Crude odds ratio
3.1 (2.6 to 3.6)2.6 (2.3 to 2.9)2.2 (2.0 to 2.4)2.4 (2.3 to 2.6)Adjusted odds ratio§
Deep venous thrombosis
841 (5.3)1237 (2.5)1641 (1.6)3719 (2.2)No (%)
10.2 (9.5 to 11.0)4.7 (4.4 to 5.0)2.9 (2.8 to 3.1)4.1 (3.9 to 4.2)Crude odds ratio
7.2 (6.7 to 7.8)4.2 (3.9 to 4.4)2.8 (2.7 to 3.0)3.7 (3.5 to 3.8)Adjusted odds ratio§
SIRS=systemic inflammatory response syndrome.
*Defined by presence of two or more of: body temperature >38°C or <36°C; heart rate >90 beats/min; respiratory rate >20 breaths/min or PaCO2 <32 mm Hg;
white blood cells >12<thin>000 cell/mm3, <4000 cells/mm3, or >10% immature (band) forms; anion gap acidosis.
†SIRS plus one of: positive result on blood culture; clinical documentation of purulence or positive culture from any site thought to be causative.
‡Sepsis and documented organ and/or circulatory dysfunction.
§Adjusted for age, sex, diabetes, smoking status, treated arterial hypertension, renal failure, cancer, bleeding disorder or anticoagulation, general anesthesia,
surgical subspecialty.
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Figures
Fig 1 Flow of participants in study of impact of sepsis on risk of postoperative arterial and venous thromboses diagram
Fig 2 Subgroup analysis for arterial thrombosis risk associated with preoperative sepsis. Arterial thrombosis includes acute
myocardial infarction or stroke that occurred intraoperatively or within 30 days after surgical procedure. Odds ratios adjusted
for age, sex, diabetes, smoking status, treated arterial hypertension, renal failure, cancer, bleeding disorder or anticoagulation,
general anaesthesia, and surgical subspecialty
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Fig 3 Subgroup analysis for risk of venous thrombosis associated with preoperative sepsis. Venous thrombosis includes
deep venous thrombosis or pulmonary embolism that occurred intraoperatively or within 30 days after surgical procedure.
Odds ratios adjusted for age, sex, diabetes, smoking status, treated arterial hypertension, renal failure, cancer, bleeding
disorder or anticoagulation, general anaesthesia, and surgical subspecialty
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